Plain-English translation of NCT04974346 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether expanding radiation therapy to include the para-aortic area (a region higher in the abdomen) improves survival and outcomes for women with locally advanced cervical cancer that has spread to pelvic lymph nodes. All participants will receive chemotherapy (cisplatin) and internal radiation (brachytherapy), but one group will also receive external radiation to a larger area of the abdomen. Researchers want to see if this extended treatment approach works better than the standard approach.
Advanced cervical cancer that has spread to lymph nodes is serious and difficult to treat. Some cancer cells may hide in higher lymph node regions that standard radiation doesn't reach. This trial is testing whether treating a larger area reduces the chance of cancer returning and improves survival.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two treatment groups. Both groups receive weekly chemotherapy (cisplatin) delivered while undergoing external beam radiation therapy over about 5-6 weeks, followed by internal radiation (brachytherapy) treatments. The difference is that one group receives radiation to the pelvis and lower abdomen, while the other group receives radiation to a larger area that also includes the upper abdomen. Throughout treatment, you'll have regular appointments for imaging, blood work, and doctor visits to monitor your progress and manage side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China